Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News ProStrakan PONV drug receives UK approval

ProStrakan PONV drug receives UK approval

8th April 2008

ProStrakan has announced that it has been granted additional significant marketing authorisations in a number of European countries, including the UK, for its injectable drug for the prevention and treatment of post-operative nausea and vomiting (PONV).

The company reports that Xomolix (droperidol), has been granted marketing authorisation under the European Decentralised Procedure launched by the firm in September 2007.

It is now approved in eight further countries, including the UK and Germany, having previously been approved in an initial eight countries, including France, Portugal and the Netherlands.

In 2007, sales of the compound reached 4.2 million pounds.

ProStrakan forecasts that Germany will be a key market for Xomolix, forecasting a potential total market size in that country of over 15 million euros (11.8 million pounds).

Wilson Totten, chief executive of ProStrakan, said: “The roll-out of Xomolix across Europe further extends ProStrakan’s pan-EU portfolio of products.”

He added that this roll out will make this product available in a number of countries where there currently exists a substantial level of patient need that is unsatisfied at present.

Last month, ProStrakan reported strong progress in the 2007 financial year, with a 22 per cent rise in product sales to 40.9 million and total revenues up 19 per cent to 45.6 million pounds.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.